ITRM: Iterum Therapeutics PLC Company Short-Term Debt

Symbol and logo of brand Iterum Therapeutics plc (ITRM)

The success of Iterum Therapeutics plc (ITRM) relies on the market recognition of the innovative sulopenem. Short-term loan debt reflects the dynamics of liability repayment, where 0.00 serves as the current metric level. Meanwhile, the company strictly minimizes environmental impact through wastewater treatment. Financial stability is maintained through the planned use of reserves to cover current regulatory costs.

ITRM (iterumtx.com) Company Short-Term Debts history from 07/04/2022 to 04/11/2026

Metric breakdowns and analytics for Iterum Therapeutics PLC (ITRM)

- current quotes and average value forecast:
Price Chart Iterum Therapeutics, plc|ITRM - Fair Value Consensus
- market capitalization information:
Market Value Iterum Therapeutics plc|ITRM - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Iterum Therapeutics|ITRM - Book Capitalization|Market Cap to Net Assets Ratio iterumtx.com|ITRM - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Iterum Therapeutics plc|ITRM - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Iterum Therapeutics, plc|ITRM - Company Aggregate Debt|Debts to Book Capitalization Iterum Therapeutics plc|ITRM - Long-Term Liabilities|Company Short-Term Debts Iterum Therapeutics|Quick Ratio iterumtx.com
- net income and valuation multiples indicators:
ITRM - Net Income
Fundamental valuation:iterumtx.com (ITRM)
Manufactured products of Iterum Therapeutics, plc

Iterum Therapeutics plc (ITRM) development of oral antibiotics to replace hospital infusions requires precise working capital management. By analyzing the short-term debt structure, an investor assesses obligations maturing within one year, which allows for the determination of liquidity risk and the efficiency of operating activity financing. The stability of this metric confirms a balanced debt load and the management's ability to maintain the pace of innovative development.

Key competitors

SMMT - Company Short-Term Debt|Company Short-Term Loans and Borrowings MRNA (Moderna Inc)|Vaxcyte Corp (PCVX) - Company Short-Term Debt|Company Current Liabilities Tarsus Corp|CRMD (CorMedix Inc.) - Company Short-Term Debts|Company Short-Term Debts serestherapeutics.com|Company Current Liabilities SPRO (Spero Therapeutics, Inc.)|SCYX (scynexis.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts ANTX (AN2 Therapeutics)|Short-Term Debt Volume PolyPid Ltd (PYPD)|LSB - Company Short-Term Debt|PHGE (BiomX Inc.) - Company Short-Term Indebtedness|SNGX: Company Short-Term Debts|Current Liabilities SXTP (60 Degrees Pharmaceuticals, Inc.)|OGEN (Oragenics, Inc.) - Company Short-Term Debts|Short-Term Debt Onconetix Corporation ONCO|Company Short-Term Debts OPGN